期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 18, 期 6, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2022.2119767
关键词
Biologics; efficacy; interleukin-17 inhibitor; psoriasis; safety
Bimekizumab, a promising treatment for moderate-to-severe plaque psoriasis, has shown efficacy and tolerability in clinical trials.
Bimekizumab, a selective interleukin (IL) 17 inhibitor, is an emerging systemic treatment for moderate-to-severe psoriasis. Although IL-19, IL-22, and IL-36 are implicated in the pathogenesis of psoriasis, IL-17 drives the activation of these interleukins and the formation of psoriatic plaques. This review assesses the efficacy, safety, and implications of bimekizumab in the treatment of moderate-to-severe psoriasis. A review of literature was conducted using the PubMed repository in March 2022. Articles in English discussing the use of bimekizumab in the treatment of psoriasis were included. One phase II and four phase III trials were included. During clinical trials, bimekizumab was more efficacious, when compared to placebo, ustekinumab, adalimumab, and secukinumab in the treatment of moderate to severe psoriasis. Bimekizumab is a promising, efficacious, and relatively tolerable emerging systemic treatment for moderate-to-severe plaque psoriasis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据